non-Hodgkins lymphoma


Also found in: Medical, Encyclopedia, Wikipedia.

non-Hodgkin's lymphoma


n.
any of several malignancies of the lymphatic system in which the cells characteristic of Hodgkin's disease are absent.
[1975–80]
References in periodicals archive ?
Scientists at Stanford University say they have developed a novel way to generate a powerful immune response targeted specifically against non-Hodgkins lymphoma, a cancer of the lymph system.
The authors estimated the global Non-Hodgkins Lymphoma (NHL) market to be worth $6.
An independent clinical study demonstrated a highly significant clinical benefit from the use of a BiovaxID formulation in relapsed non-Hodgkins lymphoma patients
Susana Inoges and colleagues at the University of Navarra (Journal of the National Cancer Institute, 98:1292-1301, Sept 20, 2006) has shown that the administration of a BiovaxID[TM] formulation given to patients with relapsed Follicular Non-Hodgkins Lymphoma following chemotherapy, with or without concomitant Rituxan[TM](1), can induce complete long-lasting remissions.
Non-Hodgkins lymphoma (NHL) is a heterogeneous disease which results in approximately 50,000 new cases and almost 25,000 deaths annually in the United States.
com/reports/c9969) has announced the addition of Stakeholder Opinions: Non-Hodgkins Lymphoma - Immunotherapy Stimulates the Market to their offering
DUBLIN, Ireland -- Non-Hodgkins Lymphoma Drugs Treating is predicted to grow to almost $5 billion USD by 2008.
IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) announced it presented updated response duration data of Zevalin(R) (ibritumomab tiuxetan) in its Phase III randomized, controlled study of 143 patients with relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkins lymphoma (NHL) at the 17th Annual Meeting of the Society for Biological Therapy in San Diego, November 8-10, 2002.
Techniclone Corporation (NASDAQ:TCLN) announced today that Schering AG, Germany, its strategic partner for its Non-Hodgkins lymphoma drug, Oncolym(R), will commence patient enrollment for the planned Phase I human clinical study shortly through its U.